Navamedic

Navamedic ASA is a Norwegian company specializing in medtech and pharmaceutical products, focusing on supplying hospitals and pharmacies. The company markets a range of pharmaceutical and medical nutrition products primarily in the Nordic countries. Among its notable innovations is the next generation digital urine meter, Sippi®, which is currently being introduced to the market. Through its commitment to improving healthcare solutions, Navamedic aims to enhance patient care and streamline medical processes.

Kathrine Andreassen

CEO

3 past transactions

Observe Medical

Post in 2024
Observe Medical ASA is a medical technology company based in Oslo, Norway, established in 2009. The company focuses on developing innovative products for patients, healthcare professionals, and hospitals, primarily in Europe and the United States. Its flagship product, Sippi, is a digital urine measuring system that automates urine production monitoring and integrates seamlessly with electronic patient journal systems. Additionally, Observe Medical has developed Sippcoat, a technology designed to inhibit the formation of biofilms in urine collection and drainage systems, enhancing patient care and safety. Through these advancements, Observe Medical aims to improve the efficiency of healthcare delivery and patient outcomes.

Sensidose

Acquisition in 2023
Sensidose AB is a drug delivery company based in Uppsala, Sweden, specializing in individualized dosing systems for pharmaceutical tablets. The company has developed an innovative electronic dosing device, known as MyFID, designed for the administration of microtablets. This device allows for precise dosage management by pre-programming specific amounts of medication to be delivered at designated times, ensuring that patients can adhere to their treatment regimens while retaining control over the dosing process. MyFID also features advanced registration capabilities, tracking the time and amount of medication dispensed, as well as recording patient-reported symptoms and reasons for taking medication. This data is accessible to both patients and physicians, facilitating informed treatment decisions and enabling continuous monitoring of disease progression. Sensidose's flagship product, Levodose, delivers levodopa for the treatment of Parkinson’s disease, demonstrating the company's commitment to enhancing therapeutic outcomes through tailored drug delivery solutions. Sensidose operates in the United States, Europe, and other international markets.

Impolin

Acquisition in 2022
Impolin is a distributor specializing in products that enhance consumer and patient health and wellbeing. It offers both proprietary brands and internationally sourced products, exporting them to various countries through third-party distributors. This enables Impolin's clients to access high-quality goods aimed at improving their overall quality of life.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.